Kornimate/medical-research-clean huggingface dataset:
dynamic 68ga-psma and 18f-fdg pet/ct analysis prior to 177lu-psma

Conditions: Prostate Cancer Metastatic

Summary: prostate cancer is a significant health issue, representing 21.8% of male cancer cases in france with over 449,000 new cases in 2018. it's the cause of 10% of cancer deaths in europe. the psma is a target for mcrpc treatment, with therapies like 177lu-psma-617 delivering radiation to cancer cells. the vision study showed that 177lu-psma-617, combined with standard care, improved survival rates significantly compared to standard care alone.the french ansm authorized 177lu-psma-617 for mcrpc under certain conditions. patients must have histologically confirmed mcrpc, be progressive despite treatment, and have psma-positive imaging. imaging assessments include psma pet/ct and 18f-fdg pet/ct to identify fdg-positive and psma-negative sites, which are associated with a poorer prognosis. parametric analysis using dynamic pet could improve lesion characterization, aiding in treatment decisions. this is the focus of the pypet study. the main objective focuses on a comparative analysis of data from dynamic parametric analysis (metabolic influx rate ki, volume of distribution vd) and static analysis (standard at 1 hour) using 18f-fdg and 68ga-psma pet/ct for diagnosing metastases, especially in the liver, lymph nodes, and bones. it aims to assess the effectiveness of these imaging techniques in accurately identifying metastatic sites.


Eligibility criteria:
inclusion criteria: * signed informed consent. * progressive metastatic castration-resistant prostate adenocarcinoma, which has been treated with taxane chemotherapy and at least one anti-androgen hormone therapy. * evaluated by 18f-fdg and 68ga-psma pet/ct prior to potential treatment with 177lu-psma. * affiliated with or beneficiary of a social protection scheme. * who stage 0 or 1. exclusion criteria: * patients unable to understand the study for any reason or comply with the trial requirements (due to language barriers, psychological issues, geographical constraints, etc.). * patients unable to undergo the examinations and/or maintain a prolonged lying position (due to back pain, etc.).

Keywords: prostate cancer 68ga-psma parametric acquisition
a usability validation of the mucopilot mobile application, a digital tool for the unsupervised objective assessment of cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the study aims to assess the usability and safety of use of mucopilot, a smartphone application that measures objective data on lung function, global exercise capacity and patient reported outcomes of patients with cystic fibrosis (cf). these data are collected during unsupervised digital tests performed in the patient's home environment between consultations. the primary objective is to validate the usability and safety of use, in order to assure that the patients use the medical device as intended without any unacceptable error of use and without unacceptable risk. the study will include 17 cf patients and will be conducted in france. they will participate in 1 inclusion visit and 1 visit in-clinic (1h30). patients will be able to download the free mucopilot mobile application. during the visit, patients will complete 3 digital tests in order to monitor cf functions (cough, dyspnea \& walking) and 1 symptom questionnaire.


Eligibility criteria:
inclusion criteria: * aged ⩾ 18 years old * patients diagnosed with cystic fibrosis * enrolled in or benefiting of a social security program * having read the information sheet and signed the informed consent form * owning a personal smartphone which version is above 14 for ios and 8 for android included with a good internet connexion * able to read french and understand pictograms on a smartphone app exclusion criteria: * history of lung transplantation * pregnant women and women who are breastfeeding * any medical condition that could interfere with the proper conduct and results of the study (clinician's judgement) * illiterate in french * inability to use a smartphone or mucopilot application * person under legal protection (including guardianship or curatorship)
examining the clinical characteristics, treatment patterns, real-world effectiveness, and healthcare resource utilization of patients with dry eye disease

Conditions: Dry Eye Disease

Summary: a prospective, non- interventional, observational, non-comparative, longitudinal cohort study design will be used to address the objectives of this study using data collected through a healthcare.

the study will identify patients with ded who newly initiated treatment with lifitegrast ophthalmic solution on or after the start of the recruitment period, which will last for 1 year since first patient first visit (fpfv) (index period). a minimum follow-up period of 6 months (post-index period) is set for each patient making the last patient last visit (lplv) 6 months after the closure of recruitment period or after the last patient recruited, whichever comes first.

Eligibility criteria:
inclusion criteria 1. age ≥18 years at index date. 2. confirmed diagnosis of ded. 3. newly started on lifitegrast ophthalmic solution within the recruitment period and not receiving lifitegrast ophthalmic solution within 6 months prior to recruitment. 4. received continuous medical care at the healthcare site defined as at least one clinical visit within 6 months. 5. clinical decision made to initiate treatment with lifitegrast ophthalmic solution prior to enrollment in the study. 6. patient agrees to be included after signing an informed consent. exclusion criteria 1. known hypersensitivity to lifitegrast or its components. 2. dry eye secondary to scarring or destruction of conjunctival goblet cells. 3. patients with active or history of ocular herpes and or other ocular infection within the last 30 days. 4. any contra-indication as per the label. 5. refusal to give signed informed consent

Keywords: dry eye disease ded nis united arab emirates
high vs low flow nasal o2 for acute hypercapnic respiratory failure

Conditions: Acute Hypercapnic Respiratory Failure; Acute Exacerbation of COPD

Summary: chronic lung conditions such as smoking related lung damage lead to breathing fail. this results in accumulation of gases such as carbon-di-oxide in the body especially during periods of illness known as exacerbation. current management of carbon-di-oxide accumulation is administration of oxygen, nebulisers, antibiotics etc and if necessary, provide a tight fitting mask around the face to provide breathing support. if this fails, then a patient is placed on a mechanical ventilator. the tight fitting mask therapy is also called non-invasive ventilation and is used widely but patients acceptability of the therapy is limited. providing a high flow of air with some oxygen could potentially provide the same benefit of the non-invasive ventilation and may also be better accepted by patients. currently the knowledge and evidence from studies suggest a beneficial role for this high flow therapy but this has not been investigated in well designed studies. in the proposed study we aim to investigate whether use of the high flow therapy reduces the need for non-invasive ventilation in patients who present with a recent onset accumulation of carbon-di-oxide in their body due to long-term lung disease. if this shows benefit, it will lead to a bigger trial with patient benefiting by reduction in the non-invasive ventilation or indeed a need for an invasive breathing machine.


Eligibility criteria:
inclusion criteria: 1. adult patients \> 18 years of age 2. acute hypercapnic respiratory failure with ph \ 6 kpa exclusion criteria: 1. age \< 18 years 2. pregnant or breast-feeding 3. patient cannot read and understand english 4. hypercapnia secondary to a drug toxicity or non-pulmonary aetiology 5. hypercapnia secondary to exacerbation of asthma 6. contraindication to niv 7. contraindication to hfnc 8. not for escalation to niv 9. ph \< 7.15 10. gcs 8 or less 11. shock defined as systolic \< 90 mmhg or a reduction by 20mmhg from usual systolic bp despite volume resuscitation 12. respiratory or cardio-respiratory arrest 13. any other indication that requires immediate invasive/non-invasive mechanical ventilation

Keywords: acute exacerbation of copd high flow nasal oxygen high flow nasal insufflation
calcium chloride for prevention of blood loss during intrapartum cesarean delivery

Conditions: Uterine Atony; Uterine Atony With Hemorrhage; Postpartum Hemorrhage; Cesarean Section Complications

Summary: postpartum hemorrhage (pph) is the leading cause of maternal morbidity and mortality worldwide. up to 80% of pph is caused by uterine atony, the failure of the uterine smooth muscle to contract and compress the uterine vasculature after delivery. laboratory and epidemiological studies show that low extracellular and serum calcium levels, respectively, decrease uterine contractility. a pilot study performed by the investigators supports the hypothesis that intravenous calcium chloride is well tolerated and may have utility in preventing uterine atony. the proposed research will establish the relationship between uterine tone and calcium through a clinical trial with an incorporated pharmacokinetic and pharmacodynamic (pk/pd) study. in a randomized, placebo-controlled, double-blind trial, investigators will establish the effect of 1 gram of intravenous calcium chloride upon quantitative blood loss and uterine tone during cesarean delivery in parturients with high risk of uterine atony. investigators will concurrently collect serial venous blood samples to measure calcium for pk/pd modeling in this pregnant study cohort. high-quality clinical research and development of novel therapeutics to manage uterine atony are critical to reduce the high maternal morbidity and mortality from pph.


Eligibility criteria:
inclusion criteria: * patient had a trial of labor for vaginal delivery prior to cesarean * patient received an oxytocin infusion for labor augmentation or induction prior to cesarean exclusion criteria: * renal dysfunction with serum cr \>1.0 mg/dl * known underlying cardiac condition * treatment with digoxin within the last 2 weeks for a maternal or fetal indication * treatment with a calcium channel blocker medication within 24 hours * hypertension necessitating intravenous antihypertensive medication within 24 hours * emergent case in which study participation could in any way impede patient care by the judgement of the obstetrician, anesthesiologist, or bedside nurse

Keywords: calcium chloride uterine atony postpartum hemorrhage cesarean delivery intrapartum cesarean
wb-ems and nutrition in patients with hematological malignancies

Conditions: Hematologic Diseases; Cachexia; Cancer; Leukemia; Myeloma; Lymphoma; Cancer

Summary: this study evaluates the effects of a whole-body electromyostimulation (wb-ems) training combined with individualized nutritional support on skeletal muscle mass, body composition, muscle strength/function, quality of life, fatigue, pain and gastrointestinal symptoms in patients with hematological malignancies 4-6 weeks before and 4-6 weeks after undergoing stem cell transplantation. within this context, this study also investigates the effect of the nutrition and exercise intervention on the period of hospitalization, period of white blood cell recovery and frequency and severity of complications (mucositis, graft-versus-host-disease, infections) after stem cell transplantation as consequences of the therapeutic immune suppression.


Eligibility criteria:
inclusion criteria: * adult patients diagnosed with hematological malignancies with an indication for stem cell transplantation * interval until transplantation: 6 weeks * ecog status 0-2 exclusion criteria: * patients with serious osteolytic lesions and increased risk of fall * simultaneous participation in other nutritional or exercise intervention trials or in the past 6 months * acute cardiovascular events * use of anabolic medications * epilepsy * severe neurological diseases * skin lesions in the area of electrodes * energy active metals in body * acute vein thrombosis * rheumatic diseases * pregnant and nursing women * psychiatric disorders with doubts about legal and cognitive capacity

Keywords: hematological malignancies leukemia myeloma lymphoma exercise nutrition protein wb-ems whole-body electromyostimulation
surepathtm liquid-based cytology and conventional smear cytology in pancreatic lesions

Conditions: Pancreatic Cancer

Summary: the surepathtm has been approved by the fda since 1997. currently, the surepathtm is used for endometrial cells, body fluids, bronchoscopy aspirates, and thyroid fine needle aspirates. there is an advantage that the denaturation is small, the density of the cells is uniform, and the read area is small so that the read time can be shortened. therefore, investigators plan to apply the surepathtm test for pancreatic eus-fna specimens. morphological comparative analysis is needed before completely replacing the existing classical smear test method. the aim of this study is to confirm that the surepathtm is not inferior and is more accurate than the classical smear test.


Eligibility criteria:
inclusion criteria: * patients who signed the agreement after the explanation * patients suspected of pancreatic cancer from radiological examinations (ct, mr, ultrasound) exclusion criteria: * those who did not agree with the study * patients older than 18 years of age * serious mental patients * patients with severe accompanying diseases (esrd, advanced copd, severe heart failure, poorly controlled blood sugar) * pregnant women * if eus is difficult due to previous surgery (billroth ii or tg with r-en-y) * patient with blood clotting abnormality * if there is a risk of tract seeding after examination
bone health in pediatric crohn's disease: a low magnitude mechanical stimulus trial

Conditions: Crohn Disease

Summary: the purpose of this 12-month double blind, placebo controlled randomized trial is to evaluate the effects of daily treatments with low magnitude mechanical stimuli on bone in 160 children with crohn disease.

skeletal growth is characterized by increases in the size of the hard outer layer of bone (cortical bone), and the density of the inner layer of bone (trabecular or "spongy" bone). children with crohn disease (cd) have numerous risk factors for impaired bone accumulation, including poor growth, delayed puberty, malnutrition, glucocorticoid therapy and inflammation. we reported that children with cd had significant deficits in trabecular bone mineral density (bmd), cortical dimensions, and muscle mass; bone deficits were strongly associated with muscle deficits. no trials of therapies that build bone or prevent bone breakdown have been conducted in chronic pediatric inflammatory diseases. the capacity to increase bone mass and dimensions in response to mechanical loading is greatest during growth. recent studies demonstrate that brief daily exposure to low magnitude mechanical stimuli (lmms) enhances bone mass and quality. this 12-month double blind, placebo controlled randomized trial will evaluate daily 10-minute treatments with lmms in 160 children with cd. trabecular bmd, cortical dimensions, and muscle area will be measured by quantitative computed tomography (qct). the lmms device monitors adherence; these data will be transmitted by modem to the psychologist who will work closely with subjects to optimize adherence. all subjects will be provided with calcium and vitamin d supplements. the primary aims are to determine if treatment with lmms results in increased trabecular bmd in the lower leg and spine and increased cortical dimensions in the lower leg in children with cd, compared with placebo controls.

Eligibility criteria:
inclusion criteria: * age 8-21 years * diagnosis of crohn disease \> 6 months * tibia vbmd z-score \< 25th%tile for age and sex exclusion criteria: * pregnancy * weight \> 250 lb * medical illness (unrelated to crohn) * cognitive/developmental disorder * do not speak english * \> 1 primary residence * unwilling to commit to 2 year study * sibling or cousin enrolled in trial
the results of multiple aspirations and injections of unicameral bone cyst by methyl prednisolone acetate

Conditions: Simple Bone Cyst

Summary: evaluation of the efficacy of methyl prednisolone injection in treatment o f simple bone cyst to prevent all possible complications as pathological fractures and to avoid prolonged restriction of physical activity

unicameral bone cysts (ubcs) are benign, fluid-filled cavities that develop in tubular and flat bones (eg,humerus, femur). these cysts tend to expand and weaken the local bone,but they are not true neoplasms. in 1876, virchow1 first described these lesions as cystic structures caused by abnormalities in local circulation. ubcs are also known as simple or solitary bone cysts. they occur almost exclusively in children and adolescents (up to 85% of cases), with a reported peak between ages 3 and14 years and the average age at diagnosis being 9 years. these lesions represent approximately 3% of all bone tumors and occur more commonly in boys than in girls (2:1). several treatment options exist for unicameral bone cysts (ubcs), including observation, steroid injection, bone marrow injection, and surgical procedures have ranged from simple curettage with autologous bone graft or allograft to sub periosteal resection with internal fixation and grafting .treatment by multiple injection of steroids produce minimal surgical approach, no hospital stay, and very low morbidity. three or four injections over a period of 12 month may be enough

Eligibility criteria:
inclusion criteria: * age .: all children eighteen years of age or younger with unicameral bone cyst * patient with previous fracture on top of unicameral bone cyst exclusion criteria: * patient age more than 18 years old * patients with malignant tumors * patients on chronic steroid treatment * pregnancy
evaluation of the effectiveness of new management techniques in reducing dental anxiety for children undergoing pulpotomy

Conditions: Anxiety

Summary: the goal of this clinical trial is to reduce dental anxiety for sixety six children undergoing pulpotomy in primary molars by using kaleidoscope glasses and tell-show-play-doh techniques and evaluation of behavior and anxiety achieved by using flaac scale, measuring heart rate and rms-pictorial scale.


Eligibility criteria:
inclusion criteria: 1. children attended the dental clinic for their first time. 2. children aged between 4 to 6 years including both boys and girls. 3. healthy children with frankl's behavior rating score 2,3 and 4 of frankl's behavior rating scale and no prior dental experience. 4. children with carious lesions in lower restorable primary molars and indicated for pulpotomy. - exclusion criteria: 1.children with known significant visual impairments or psychological problems. 2. children suffering from systemic diseases or special health care needs.

Keywords: childhood dental anxiety, behavior management.
assessing cervical sensorimotor control with vr in chronic neck pain

Conditions: Neck Pain; Virtual Reality; Sensorimotor

Summary: to develop a cervical smc vr assessment system incorporating different smc tests and to compare cervical smc performance using this self-developed vr assessment system in individuals with and without cnp


Eligibility criteria:
inclusion criteria: 1. for patients with chronic neck pain: * pain was unilateral or bilateral between the superior nuchal line and 1st thoracic vertebra, * neck pain persisting for 3 months and above, * average pain intensity of last pain episode was between 2 and 8 based on the numerical rating scale (nrs) 2. healthy asymptomatic adults: * do not have any complaints of current pain and impairments of neuromusculoskeletal systems within the last 6 months exclusion criteria: * acute or the first onset of neck pain * previous fracture or surgery of the spine * diagnosed cardiopulmonary diseases, for example, chronic obstructive pulmonary disease, pulmonary tuberculosis, asthma, chronic bronchitis, pulmonary emphysema * diagnosed gastrointestinal and abdominal conditions which may interfere daily activities within the past 6 months * medical conditions that may affect balance and study procedures (e.g. neurological diseases, vestibular disorders, malignant tumors) * metabolic diseases such as anemia and diabetes * smoking, plan to pregnant or in pregnancy * psychological disorders (affect questionnaire responses) * unable to walk independently * corrected visual abnormalities or individuals unable to wear contact lenses for vision correction due to the potential interference of wearing vr head-mounted display with glasses

Keywords: sensorimotor control virtual reality chronic neck pain cervical
a study looking at how different doses of study medicine (inno8) works in the body of healthy men

Conditions: Haemophilia A

Summary: this study will test how different doses of study medicine (inno8) work in the healthy men. the purpose of this study is to prove safety of inno8 in healthy men, which will support further development of inno8 in people with haemophilia a. the study is divided into two parts, called the single ascending dose (sad) part and multiple ascending dose (mad) part, and each part will have more than one cohort (like sub-parts). no matter which part the participants will be enrolled in, they will either get the study medicine (inno8) or a dummy medicine that looks like the study medicine but has no effect on the body (placebo). which treatment participants get is decided by chance. the study medicine is a new medicine that cannot yet be prescribed by doctors. in the sad part participants will receive a single injection of study medicine or placebo, and the study will last for up to 9 weeks. in the mad part, participants will receive 1-2 tablets of study medicine or placebo daily for 10 days, and the study will last for up to 11 weeks.


Eligibility criteria:
inclusion criteria: * male * age 18-45 years (both inclusive) at the time of signing informed consent * body mass index between 18.5 and 29.9 kilogram per square meter (kg/m\^2) (both inclusive) * body weight between 60.0 and 100.0 kilogram (kg) (both inclusive) * considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator exclusion criteria: * factor viii activity greater than or equal to (≥) 150% at screening * increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis * any clinical signs or established diagnosis of venous or arterial thromboembolic disease * any of the thrombophilia markers listed below: * protein c, protein s or antithrombin below the lower normal laboratory range * factor ii activity, activated protein c resistance, lupus anticoagulant, anti-cardiolipin antibody (igg and igm) or anti-β2 glycoprotein i antibody (igg and igm) outside the normal laboratory range at screening